US 2020/0369771 A1 · MONOCLONAL ANTIBODY TO PD-L1

Monoclonal antibody to pd-l1

AssigneeJoint Stock Company “Biocad”

InventorsAndrey Borisovich ULITIN, Victoria Mikhailovna EKIMOVA, Ekaterina Vladimirovna SOFRONOVA,, Yulia Sergeevna CHERNYKH, Sergei Andreevich AGEEV, Anna Konstantinovna VLADIMIROVA, Aleksei Aleksandrovich ALEKSANDROV, Pavel Alekseevich GREBNEV, Valery Vladimirovich SOLOVYEV, Iakov Iurevich USTIUGOV, Pavel Andreevich IAKOVLEV, Timofey Aleksandrovich NEMANKIN, Dmitry Valentinovich MOROZOV

Life of this patent

Estimating the term…

Abstract

The present invention relates to the field of biotechnology and provides antibodies that specifically binds to PD-L1. The invention also relates to DNA encoding said antibodies, to corresponding expression vectors and to methods of producing, and to methods of treatment using said antibodies.

Claims34

Dependent claims

A monoclonal antibody or an antigen binding fragment thereof that specifically binds to PD-L1 comprising:

a heavy chain variable domain comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:
3;
a light chain variable domain comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:
7.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

16/605,865Filed 11 Apr 2018

Priority

RU 201711314117 Apr 2017

Published

26 Nov 2020

Term ends

Not estimatedThe source records don’t support an estimate.

Classification18 codes

C07K 16/2827
Against the immunoglobulin superfamily: against B7 molecules, e.g. CD80, CD86
A61K 39/39558
Against materials from animals: against tumor tissues, cells, antigens
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61P 35/00
Antineoplastic agents